Q2 EPS Forecast for OnKure Therapeutics Lifted by Analyst

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – Stock analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of OnKure Therapeutics in a note issued to investors on Monday, July 20th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.39) per share for the quarter, up from their prior forecast of ($0.93). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.94) EPS.

Several other research analysts have also weighed in on the company. JonesTrading lowered OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings raised OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $21.00.

OnKure Therapeutics Stock Performance

Shares of NASDAQ OKUR opened at $4.32 on Wednesday. The stock has a 50 day moving average price of $4.19 and a 200 day moving average price of $3.75. OnKure Therapeutics has a 52 week low of $1.91 and a 52 week high of $5.38. The stock has a market capitalization of $174.53 million, a PE ratio of -1.00 and a beta of 0.27.

OnKure Therapeutics (NASDAQ:OKUR) last released its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37).

Institutional Investors Weigh In On OnKure Therapeutics

A number of institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of OnKure Therapeutics in the second quarter valued at approximately $25,000. Jane Street Group LLC acquired a new stake in OnKure Therapeutics during the 4th quarter worth approximately $56,000. Hsbc Holdings PLC acquired a new stake in OnKure Therapeutics during the 4th quarter worth approximately $58,000. Rangeley Capital LLC bought a new stake in OnKure Therapeutics in the 2nd quarter valued at $71,000. Finally, Barclays PLC boosted its stake in OnKure Therapeutics by 4,286.8% in the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after purchasing an additional 26,621 shares during the period. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.